NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE Drug Patent Profile
Which patents cover Norepinephrine Bitartrate In 0.9% Sodium Chloride, and what generic alternatives are available?
Norepinephrine Bitartrate In 0.9% Sodium Chloride is a drug marketed by Baxter Hlthcare Corp, Inforlife, and Long Grove Pharms. and is included in three NDAs. There are ten patents protecting this drug.
The generic ingredient in NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE is norepinephrine bitartrate. There is one drug master file entry for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Norepinephrine Bitartrate In 0.9% Sodium Chloride
A generic version of NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE was approved as norepinephrine bitartrate by MEITHEAL on March 3rd, 2003.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE?
- What are the global sales for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE?
- What is Average Wholesale Price for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE?
Summary for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
Recent Clinical Trials for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Siriraj Hospital | PHASE1 |
| Visarat Palitnonkiat | PHASE1 |
| Hassan II University | PHASE4 |
See all NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE clinical trials
Pharmacology for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
| Drug Class | Catecholamine |
US Patents and Regulatory Information for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE is protected by ten US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long Grove Pharms | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214628-003 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Long Grove Pharms | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214628-003 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Long Grove Pharms | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214628-003 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
See the table below for patents covering NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 3174640 | SYSTEME DE RECIPIENT SCELLE CONDITIONNE DE STOCKAGE STABLE DE FORMULATION PHARMACEUTIQUE SENSIBLE A L'OXYGENE (PACKAGED, SEALED CONTAINER SYSTEM FOR STABLE STORAGE OF AN OXYGEN SENSITIVE PHARMACEUTICAL FORMULATION) | ⤷ Start Trial |
| European Patent Office | 4114336 | SYSTÈME DE RÉCIPIENT SCELLÉ CONDITIONNÉ DE STOCKAGE STABLE DE FORMULATION PHARMACEUTIQUE SENSIBLE À L'OXYGÈNE (PACKAGED, SEALED CONTAINER SYSTEM FOR STABLE STORAGE OF AN OXYGEN SENSITIVE PHARMACEUTICAL FORMULATION) | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2021178946 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |

